Al-Awadhi Rana, AlRoomy Moody, Dashti Hawraa, Kapila Kusum
Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Kuwait University, Jabriyah City, State of Kuwait.
Cytology Laboratory, Mubarak Al-Kabeer Hospital, Ministry of Health, Kuwait.
J Cytol. 2024 Jul-Sep;41(3):157-161. doi: 10.4103/joc.joc_27_24. Epub 2024 Jul 18.
Persistent infection with high-risk human papillomavirus (hr-HPV) types is associated with high-grade cervical abnormalities.
The aim of the study was to find most hr-HPV types causing persistent infection in abnormal cytological samples using Aptima HPV testing and discuss the compatibility of the Gardasil 9 vaccine in targeting most types.
The study was conducted in a cytology laboratory in a tertiary hospital.
This is a retrospective observational study.
Cytology and HPV Aptima test reports were obtained for abnormal cervical samples for a 6-year period.
Pearson Chi-square test.
Reports of 2834 abnormal cervical samples were analyzed. Aptima testing was positive in 21% of samples, including 92% of squamous cell carcinoma (SCC), 76.4% of the high-grade squamous intraepithelial lesion (HSIL), 52% of low-grade squamous intraepithelial lesion (LSIL), 40% of adenocarcinoma (ADC), and 21% of atypical squamous cells that cannot exclude HSIL (ASC-H). The Aptima other hr-HPV group was most common (60%), HPV16 was 26%, HPV18/45 was 9.6%, and double HPV infection was 4.3%. HPV16 was the most common infection in HSIL+ cases. HPV infection was most common in age groups (30-39) and (40-49), and a shift to age groups (50-59) and ≥60 was seen in HSIL+ cases.
This study is the first of its kind in correlating age with hr-HPV and cytology findings in the Middle East and adds to previous knowledge related to the prevalence and Aptima testing of HPV. The outcome could be used as a baseline for the Gardasil 9 vaccine and for the assessment of its effectiveness after three or five years from initiation.
高危型人乳头瘤病毒(hr-HPV)的持续感染与高级别宫颈病变相关。
本研究旨在通过Aptima HPV检测找出导致异常细胞学样本持续感染的大多数hr-HPV类型,并讨论九价重组人乳头瘤病毒吸附疫苗(佳达修9)针对大多数类型的适用性。
本研究在一家三级医院的细胞学实验室进行。
这是一项回顾性观察研究。
获取了6年间宫颈异常样本的细胞学和HPV Aptima检测报告。
Pearson卡方检验。
分析了2834份宫颈异常样本的报告。Aptima检测在21%的样本中呈阳性,其中包括92%的鳞状细胞癌(SCC)、76.4%的高级别鳞状上皮内病变(HSIL)、52%的低级别鳞状上皮内病变(LSIL)、40%的腺癌(ADC)以及21%不能排除高级别鳞状上皮内病变的非典型鳞状细胞(ASC-H)。Aptima其他hr-HPV组最为常见(60%),HPV16占26%,HPV18/45占9.6%,双重HPV感染占4.3%。HPV16是HSIL+病例中最常见的感染类型。HPV感染在年龄组(30 - 39岁)和(40 - 49岁)最为常见,而在HSIL+病例中则出现向年龄组(50 - 59岁)和≥60岁的转变。
本研究是中东地区首例将年龄与hr-HPV及细胞学结果相关联研究,补充了先前关于HPV患病率及Aptima检测的知识。该结果可作为九价重组人乳头瘤病毒吸附疫苗(佳达修9)的基线,并用于评估其接种三年或五年后的效果。